In patients with chronic kidney disease (CKD G5D) who are on dialysis and present with elevated intact parathyroid hormone (iPTH), active PTH-lowering intervention becomes necessary. This protocol addresses the specific management approach and biochemical targets for renal osteodystrophy in this population.
CKD G5D on dialysis with elevated intact PTH, in the context of chronic kidney disease — requiring targeted PTH-lowering therapy.
Intact PTH (iPTH) maintained within approximately 2 to 9 times the upper normal limit for the assay.
The protocol centres on agents in the vitamin D class, and potentially additional pharmacological options — used individually or in combination depending on specific clinical criteria outlined in the full regimen.
DOI: 10.1038/ki.2009.191